(3R)-5-oxo-N-[5-(3-propylphenyl)-1-(trifluoromethyl)pyrazol-3-yl]pyrrolidine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3R)-5-oxo-N-[5-(3-propylphenyl)-1-(trifluoromethyl)pyrazol-3-yl]pyrrolidine-3-carboxamide
• 化学式: C₁₈H₁₉F₃N₄O₂
• 分子量: 380.4
• InChiKey: SVUBLYCTTBTAMX-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：US20190352284A1

  公开（公告）日：2019-11-21

  An object of the present invention is to provide a methyllactam ring compound that has an SGLT1 inhibitory activity and is useful for a drug, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof. A compound of Formula [I]: or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.

  本发明的一个目的是提供一种具有SGLT1抑制活性且适用于药物的甲基乳酰胺环化合物，或其药用盐，包括它的药物组合物以及其药用。提供一种化合物的公式[I]：或其药用盐，包括它的药物组合物以及其药用。
• PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：JAPAN TOBACCO INC.

  公开号：US20150183763A1

  公开（公告）日：2015-07-02

  The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

  本发明提供了一种具有SGLT1抑制活性的吡唑化合物，或其药学上可接受的盐，其一般式[Ib]如下，以及包含其的药物组合物和其药用：其中每个符号如描述中所定义。
• THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE
  申请人：Japan Tobacco Inc.

  公开号：EP4026564A1

  公开（公告）日：2022-07-13

  One purpose of the present invention is to provide therapy or prophylaxis of diabetes, obesity, or diabetic complications. The present invention provides a therapeutic or prophylactic medicine that is for diabetes, obesity, or diabetic complications, and that is characterized by combinational use of an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors; and a therapeutic or prophylactic method that is for diabetes, obesity, or diabetic complications, and that is characterized by administering an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors.

  本发明的一个目的是提供糖尿病、肥胖症或糖尿病并发症的治疗或预防。本发明提供了一种治疗或预防糖尿病、肥胖症或糖尿病并发症的药物，其特点是联合使用SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物；以及一种治疗或预防糖尿病、肥胖症或糖尿病并发症的治疗方法，其特点是给予SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物。
• Methyllactam ring compound and pharmaceutical use thereof
  申请人：Japan Tobacco Inc.

  公开号：US11014910B2

  公开（公告）日：2021-05-25

  An object of the present invention is to provide a methyllactam ring compound that has an SGLT1 inhibitory activity and is useful for a drug, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof. A compound of Formula [I]: or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.

  本发明的目的是提供一种具有SGLT1抑制活性并可用于药物的甲基内酰胺环化合物或其药学上可接受的盐、由其组成的药物组合物及其药物用途。一种式[I]化合物： 或其药学上可接受的盐、由其组成的药物组合物及其药物用途。
• US8846746B2
  申请人：——

  公开号：US8846746B2

  公开（公告）日：2014-09-30